Prognostic Impact of Varices and Hemorrhagic Events in Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab
In unresectable HCC patients treated with atezolizumab plus bevacizumab, varices increase bleeding risk. However, proactive management and careful monitoring could mitigate their impact on OS and help increase the DCR.
Authors
- Moon Haeng Hur (ORCID: https://orcid.org/0000-0001-5463-6782)
- Eun Ju Cho (ORCID: https://orcid.org/0000-0002-2677-3189)
- Jung‐Hwan Yoon (ORCID: https://orcid.org/0000-0002-9128-3610)
- Yun Bin Lee (ORCID: https://orcid.org/0000-0002-3193-9745)
- Su Jong Yu (ORCID: https://orcid.org/0000-0001-8888-7977)
- Jeayeon Park (ORCID: https://orcid.org/0000-0003-1155-0588)
- Dong Ho Lee (ORCID: https://orcid.org/0000-0001-8983-851X)
- Jeong‐Hoon Lee (ORCID: https://orcid.org/0000-0002-0315-2080)
- Yoon Jun Kim (ORCID: https://orcid.org/0000-0001-9141-7773)
Institutions
- Seoul National University Hospital (KR)
Publication Details
- Journal
- Gut and Liver
- Published
- 2025-11-11
- DOI
- https://doi.org/10.5009/gnl250133
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00